Harnett P R, Bell D R, Hillcoat B L, Woods R L, Levi J A, Rome R M, Campbell J C, Tattersall M H
Ludwig Institute for Cancer Research (Sydney Branch), University of Sydney, New South Wales, Australia.
Gynecol Oncol. 1988 Jun;30(2):159-62. doi: 10.1016/0090-8258(88)90019-4.
Thirty-five patients with advanced epithelial ovarian carcinoma (24 untreated, 11 previously treated with alkylating agents) were treated with a combination of cisplatin and etoposide (VP16-213). Tumor response (i.e., complete response and partial response) was seen in 16 of the 35 patients (i.e., 46%), with 5 complete responses. The response rate in previously untreated patients was 54%, but only 27% in previously treated patients. The median survival was 42 weeks. The toxicity of this regimen was severe. Twelve patients became severely myelosuppressed, including one septic death while severely neutropenic. Treatment with cisplatin and etoposide produces only average tumor response rates and patient survival, but is associated with severe toxicity. There is no evidence of synergy between cisplatin and VP16 in this study.
35例晚期上皮性卵巢癌患者（24例未接受过治疗，11例曾接受过烷化剂治疗）接受了顺铂和依托泊苷（VP16 - 213）联合治疗。35例患者中有16例（即46%）出现肿瘤反应（即完全缓解和部分缓解），其中5例完全缓解。未接受过治疗的患者缓解率为54%，而曾接受过治疗的患者仅为27%。中位生存期为42周。该治疗方案的毒性严重。12例患者出现严重骨髓抑制，其中1例在严重中性粒细胞减少时发生败血症死亡。顺铂和依托泊苷联合治疗仅产生中等的肿瘤反应率和患者生存率，但伴有严重毒性。本研究中没有证据表明顺铂和VP16之间存在协同作用。
